A compartmental absorption and transit model for estimating oral drug absorption.

This report describes a compartmental absorption and transit model to estimate the fraction of dose absorbed and the rate of drug absorption for passively transported drugs in immediate release products. The model considers simultaneous small intestinal transit flow and drug absorption. Both analytical and numerical methods were utilized to solve the model equations. It was found that the fraction of dose absorbed can be estimated by F(a) = 1-(1+0.54 P(eff))(-7), where P(eff) is the human effective permeability in cm/h. A good correlation was found between the fraction of dose absorbed and the effective permeability for ten drugs covering a wide range of absorption characteristics. The model was able to explain the oral plasma concentration profiles of atenolol.

[1]  Lawrence X. Yu,et al.  Characterization of small intestinal transit time distribution in humans , 1998 .

[2]  W. Crouthamel,et al.  Animal models for oral drug delivery in man : in situ and in vivo approaches , 1983 .

[3]  G L Amidon,et al.  Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. , 1996, Advanced drug delivery reviews.

[4]  M. Eichelbaum,et al.  Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration. , 1982, Arzneimittel-Forschung.

[5]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[6]  F. Tse,et al.  Pharmacokinetics of Fluvastatin After Single and Multiple Doses in Normal Volunteers , 1992, Journal of clinical pharmacology.

[7]  W. M. Heller.  American Hospital Formulary Service , 1959 .

[8]  L F Prescott,et al.  Kinetics of acetaminophen absorption and gastric emptying in man , 1978, Clinical pharmacology and therapeutics.

[9]  R. Schoenwald,et al.  Furosemide (Frusemide) A Pharmacokinetic/Pharmacodynamic Review (Part I) , 1990, Clinical pharmacokinetics.

[10]  R. Cody,et al.  Clinical Pharmacokinetics of the Angiotensin Converting Enzyme Inhibitors , 1985, Clinical pharmacokinetics.

[11]  Lawrence X. Yu,et al.  Compartmental transit and dispersion model analysis of small intestinal transit flow in humans , 1996 .

[12]  H. Lennernäs,et al.  Intestinal drug absorption during induced net water absorption in man; a mechanistic study using antipyrine, atenolol and enalaprilat. , 1994, British journal of clinical pharmacology.

[13]  Davies Ds.  Pharmacokinetics of terbutaline after oral administration. , 1984 .

[14]  G. Amidon,et al.  Human effective permeability data forrurosemide, hydrochlorthiazide, ketoprofen and naproxen to be used in the proposed biopharmaceutical drug classification system for IR-products , 1996 .

[15]  H. Lennernäs,et al.  The lack of effect of induced net fluid absorption on the in vivo permeability of terbutaline in the human jejunum. , 1995, Journal of drug targeting.

[16]  J. Wagner.  Pharmacokinetics for the Pharmaceutical Scientist , 1993 .

[17]  R. Shanks,et al.  Clinical Pharmacokinetics of β-Adrenoceptor Antagonists , 1987 .

[18]  W. D. Mason,et al.  Kinetics and absolute bioavailability of atenolol , 1979, Clinical pharmacology and therapeutics.

[19]  G. Amidon,et al.  Physicochemical model for dose-dependent drug absorption. , 1984, Journal of pharmaceutical sciences.